1. PO.6.134 Safety and tolerability of nipocalimab administered at different rates of intravenous infusion in healthy adults: a phase 1 placebo-controlled single-dose study. (27th September 2022) Authors: Leu, J; Vermeulen, A; Zazzetti, F; Ling, L Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO.6.137 Design of a phase 2, multicenter, randomized, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of nipocalimab in adults with active systemic lupus erythematosus. (27th September 2022) Authors: Liu-Walsh, F; Van Hartingsveldt, B; Zuraw, Q; Hoffman, RW; Rooney, T; Gao, S; Gordon, R; Leu, JH; Berhanu Debella, A; Calderon, C; Zazzetti, F; Vratsanos, G Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗